Drug Profile
Filgrastim biosimilar - Dong-A ST
Alternative Names: DA 3030; Leucostim; Leukopoeitin - Dong-A ST; Leukostim®; rhG-CSFLatest Information Update: 16 Dec 2021
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetic neuropathies
Highest Development Phases
- Marketed Neutropenia
- Phase II Diabetic neuropathies
Most Recent Events
- 07 Jan 2020 Clinical development is still ongoing for Neutropenia (Prevention, Chemotherapy-induced) in Indonesia (SC) (NCT03343145)
- 29 Jul 2019 Dong-A ST completes a phase III trial in Neutropenia (Prevention, Chemotherapy-induced) in Indonesia (SC) (NCT03343145)
- 05 May 2016 Biocad plans a phase I trial for Leucocytosis (In volunteers) in Russia (SC) (NCT02762799)